Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)
Male hypogonadism (low testosterone [low T]) is a condition characterized by impaired spermatogenesis and low serum testosterone. The majority of cases are caused by low T driven by age or comorbidities (e.g., obesity). Testosterone replacement therapy (TRT), which aims to increase overall serum testosterone levels, is the cornerstone of treatment and is primarily administered via injection, oral, or topical means. The approval of oral testosterone undecanoate medications like Jatenzo and Tlando will help in reducing the risk of adverse reactions at the injection site that are typical of intramuscular testosterone injections. However, a key drawback of TRT is decreased spermatogenesis, and some alternative therapies for low T focus on stimulating gonadotropins to preserve fertility. Additionally, the FDA has cautioned against the use of TRT because of the possibility of increased cardiac risk. Here, we evaluate U.S. physician prescribing and treatment strategies in this arena based on patient-level claims data.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed low T patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed low T patients?
- How have testosterone cypionate injection, testosterone enanthate injection, testosterone gel, Jatenzo, and others been integrated into the treatment algorithm, and what are their source of business?
- What percentage of low T patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of low T patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Halozyme, Endo Pharmaceuticals, AbbVie, Tolmar Pharmaceuticals.
Key drugs: testosterone cypionate, Xyosted, testosterone enanthate, testosterone 1.62% gel, clomiphene citrate, anastrozole, Testopel, Jatenzo, Tlando.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Male Hypogonadism - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Male Hypogonadism (Low Testosterone) (US)
- Treatment Algorithms CDA Low Testosterone (Male Hypogonadism) US May 2023
- Treatment Algorithms CDA Low Testosterone (Male Hypogonadism) 2023 Dashboard
Sukhvinder Singh, M.Tech., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has several years of experience providing research and analytics support in the pharmaceutical domain. He has worked in numerous therapy areas, including ophthalmology, dermatology, neurology, and rare diseases. Prior to joining Clarivate, Mr. Singh was an assistant project manager on the forecasting and analytics team at DelveInsight Business Research. He was responsible for preparing epidemiology and market research reports, which included pipeline assessments, sales forecasting, and commercial opportunity assessments. He earned his master’s degree in technology and biotechnology at Amity University in Noida, India.